Scribe Therapeutics (SCTX) Stock Forecast: StockMap's 2-Week Call
SCTX stock forecast: StockMap's model calls Scribe Therapeutics Strong Underperform for the two weeks after the Nov 18 close: it expects SCTX to trail the growth index. It is a call on the gap, not a price target. Right in 4 of 6 two-week windows on SCTX since Aug 26; by chance, a call on the same dates was right 61% of the time.
Scribe Therapeutics last closed at $14.05, -10.91% on the session.
Against the IVW growth benchmark the position is -10.93% over the forecast window.
Scribe Therapeutics' market cap is $259.32M as of November 18, 2026.
Calls down ↘: the model's call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -75 (behind).
Where SCTX sits: sized by market cap, coloured by the day's move.
The read is built from 11 underlying insights — 0 bullish and 11 bearish.
Agreement across those insights is 100%.
38 daily calls for SCTX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
Scribe Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Scribe Therapeutics as the 218th largest of the 393 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 195 Moderate Underperform, 141 Neutral, 42 Strong Underperform and 15 Moderate Outperform.
On that composite Scribe Therapeutics ranks 388th of 393 in the group, against a group median of -0.27.